Uterine Fibroids




11 months

Uterine Fibroids: ASTEROID 3

Official Title

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3)

Study Summary

The primary objective of this study is to show superiority in the treatment of HMB of vilaprisan in subjects with uterine fibroids compared to placebo. The secondary objectives of this study are to additionally evaluate the efficacy and safety of vilaprisan in subjects with uterine fibroids.

Eligibility and Recruitment Information

Eligible Genders Female
Eligible Ages 18-100
Inclusion Women, 18 years or older in good General health Diagnosis of uterine fibroid(s) documented by ultrasound at screening with at least 1 fibroid with largest Diameter ≥ 30 mm and < 120 mm Heavy menstrual bleeding (HMB) in at least 2 bleeding periods during the Screening period each with blood loss volume of >80.00 mL documented by alkaline hematin (AH) method An endometrial biopsy performed during the Screening period without significant histological disorder such as endometrial hyperplasia (including simple hyperplasia) or other significant endometrial pathology Use of an acceptable non-hormonal method of contraception (ie, either male condom, cap, diaphragm or sponge, each in combination with spermicide) starting at Visit 1 until the end of the study
Exclusion Pregnancy or lactation (less than 3 month since delivery, abortion, or lactation before start of Treatment) Hypersensitivity to any ingredient of the study drug Any condition requiring immediate blood transfusion Laboratory values outside inclusion range before randomization and considered as clinically relevant. Any diseases, conditions, or medications that can compromise the function of the body systems and could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the study drug Any diseases or conditions that might interfere with the conduct of the study or the interpretation of the results Abuse of alcohol, drugs, or medicines (eg, laxatives) Use of other treatments that might interfere with the conduct of the study or the interpretation of the results Undiagnosed abnormal genital bleeding
Start Date
Compensation $1025
Location Orlando, FL

Study Information

Condition Uterine Fibroids
Study Phase 3

Administrative Information

Study ID NCT03400943

Apply for this study

Please include your first name.
Please include your last name.
Please include a valid email address.
Thank you for applying.
Sorry, something wen't wrong. Please contact us for support.